Oracle and AstraZeneca agree to explore AI use in clinical trials and patient care

Oracle said on October 20, 2026 that it has reached a non-binding agreement with AstraZeneca to explore how AI and real-world data can help clinicians identify eligible patients for clinical trials, speed up evidence generation and bring research insights into everyday care.

Oracle said the companies plan to explore selected use cases aimed at improving clinical-trial efficiency and success, including helping care teams find eligible patients earlier and widening patient access to trials. Oracle named patient recruitment as an obstacle in clinical trials.

AstraZeneca Chief Executive Officer Pascal Soriot said the collaboration brings healthcare and AI leaders together to speed the path from medicine discovery to patient care, combining AstraZeneca's scientific expertise with Oracle's data and technology.

Oracle Chief Executive Officer Mike Sicilia said AI can help turn scientific innovation into better patient outcomes, and that the companies have an opportunity to accelerate research and connect more patients to clinical trials.

Oracle said the companies intend to explore a continuous learning model in which research and routine care inform future study design, safety monitoring and patient care. Oracle said the companies plan to establish shared governance, reusable technical components and agreed outcome measures to assess results and determine whether successful approaches could extend across disease areas and geographies.